RecruitingNCT06375213

Investigating Neurocognitive Disorders Epidemiology

Sponsor

King Chulalongkorn Memorial Hospital

Enrollment

990 participants

Start Date

Aug 24, 2023

Study Type

OBSERVATIONAL

Conditions

Dementia Cognitive Decline Alzheimer Disease

Summary

This is a prospective cohort study with the main purpose of predicting progression neurocognitive disorders in Thai population. The main predictor variables to be evaluated are plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined using statistical/computational modeling. Additionally, it seeks to evaluate biomarkers for diagnosing disease pathologies, understand their correlation with clinical outcomes, and explore the socioeconomic impact of neurocognitive disorders. The study invites both participants for biospecimen collection, structured interviews, and cognitive examinations and schedules follow-up visits annually or biennially.

Eligibility

Min Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how memory and thinking problems develop over time — from healthy aging to mild forgetfulness to dementia — in people in Thailand. **You may be eligible if...** - You are a Thai speaker who does not need a translator - You fall into one of three groups: completely healthy cognition, mild memory or thinking difficulties (but not dementia), or diagnosed dementia - You are willing to complete cognitive (thinking and memory) tests **You may NOT be eligible if...** - You have a serious uncontrolled neurological or psychiatric illness - You have a severe unstable medical condition or organ failure that would affect your ability to participate - You cannot communicate in Thai Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPlasma tau phosphorylated at Thr217

Plasma concentration of tau protein phosphorylated at Thr217 as measured on the Meso Scale Discovery, single molecule array (Simoa) or the in-house mass spectrometry platform.

OTHERNeurocognitive examination

Traditional (paper and pencil) neurocognitive/neuropsychiatric examination performed by certified psychologists. This includes: Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Wechsler Memory Scale - Fourth Edition (WMS-IV), Neuropsychiatric Inventory - Questionnaire (NPI-Q), Thai Geriatric Depression Scale (TGDS), General Anxiety Disorder - 7 (GAD-7), The Barthel activities of daily living (ADL) Index, Chula ADL Index.